Institute of Chemistry and Biology of Membranes and Nano-objects (CBMN) UMR-5248, CNRS, University of Bordeaux, INP, Allée Geoffroy St Hilaire, 33600 Pessac, France
Cédric Pisani
The French Alternative Energies and Atomic Energy Commission (CEA), Biosciences and Biotechnologies Institute (BIAM), 30200 Bagnols-sur-Cèze, France
Christophe Dorandeu
Institute Charles Gerhardt of Montpellier (ICGM), Place E. Bataillon, 34095 Montpellier, France
Jeff L. Nyalosaso
Institute Charles Gerhardt of Montpellier (ICGM), Place E. Bataillon, 34095 Montpellier, France
Clarence Charnay
Institute Charles Gerhardt of Montpellier (ICGM), Place E. Bataillon, 34095 Montpellier, France
Morgane Daurat
NanoMedSyn, 15 Avenue Charles Flahault, 34090 Montpellier, France
Afitz Da Silva
NanoMedSyn, 15 Avenue Charles Flahault, 34090 Montpellier, France
Jean-Marie Devoisselle
Institute Charles Gerhardt of Montpellier (ICGM), Place E. Bataillon, 34095 Montpellier, France
Jean-Charles Gaillard
Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI), CEA, INRA, 30207 Bagnols-sur-Cèze, France
Jean Armengaud
Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Service de Pharmacologie et Immunoanalyse (SPI), CEA, INRA, 30207 Bagnols-sur-Cèze, France
Odette Prat
The French Alternative Energies and Atomic Energy Commission (CEA), Biosciences and Biotechnologies Institute (BIAM), 30200 Bagnols-sur-Cèze, France
Marie Maynadier
NanoMedSyn, 15 Avenue Charles Flahault, 34090 Montpellier, France
Magali Gary-Bobo
Max Mousseron Biomolecule Institute of Montpellier (IBMM), 15 Avenue Charles Flahault, 34090 Montpellier, France
Marcel Garcia
NanoMedSyn, 15 Avenue Charles Flahault, 34090 Montpellier, France
Joël Chopineau
Institute Charles Gerhardt of Montpellier (ICGM), Place E. Bataillon, 34095 Montpellier, France
Yannick Guari
Institute Charles Gerhardt of Montpellier (ICGM), Place E. Bataillon, 34095 Montpellier, France
Careful analysis of any new nanomedicine device or disposal should be undertaken to comprehensively characterize the new product before application, so that any unintended side effect is minimized. Because of the increasing number of nanotechnology-based drugs, we can anticipate that regulatory authorities might adapt the approval process for nanomedicine products due to safety concerns, e.g., request a more rigorous testing of the potential toxicity of nanoparticles (NPs). Currently, the use of mesoporous silica nanoparticles (MSN) as drug delivery systems is challenged by a lack of data on the toxicological profile of coated or non-coated MSN. In this context, we have carried out an extensive study documenting the influence of different functionalized MSN on the cellular internalization and in vivo behaviour. In this article, a synthesis of these works is reviewed and the perspectives are drawn. The use of magnetic MSN (Fe3O4@MSN) allows an efficient separation of coated NPs from cell cultures with a simple magnet, leading to results regarding corona formation without experimental bias. Our interest is focused on the mechanism of interaction with model membranes, the adsorption of proteins in biological fluids, the quantification of uptake, and the effect of such NPs on the transcriptomic profile of hepatic cells that are known to be readily concerned by NPs’ uptake in vivo, especially in the case of an intravenous injection.